The comparison of saliva visfatin level before and three months after NSPT among cases with periodontitis. by Zahra Tajik (20752452)

Subjects:

The comparison of GCF visfatin level before and three months after NSPT among cases with periodontitis and T2DM. by Zahra Tajik (20752452)

Subjects:

List of excluded studies. by Zahra Tajik (20752452)

Subjects:

Comparison of step rate, step length, stance time, and flight time between tasks in eight intervals from the start to the 40 m mark. by Shinnosuke Hase (20917896)

NLSs can significantly impact intranuclear stages of HIV-1 infection. by Nicholas Rohlfes (20577485)

Trends of incident opioid users, L-TOT users, and L-TOT discontinuers between 2009 and 2013. by Qian Cai (112039)

Subjects:

The yearly numerator, denominator and rate of incident opioid users, L-TOT users and L-TOT discontinuers from 2009 to 2019. by Qian Cai (112039)

Subjects:

Incidence rate ratios of negative binominal regression models for yearly rates of incident opioid users, L-TOT users and L-TOT discontinuers during 2009–2013 and 2015–2019. by Qian Cai (112039)

Subjects:

Demographic, comorbidity, concurrent drug, and opioid characteristics, among L-TOT users and L-TOT discontinuers between 2009–2019. by Qian Cai (112039)

Subjects:

Sensitivity and subgroup analysis between higher TV watching time and cognitive scores. by Hattapark Dejakaisaya (22238613)

Subjects:

Sensitivity and subgroup analysis of conventional meta-analysis of TV watching time and risk of cognitive impairment. by Hattapark Dejakaisaya (22238613)

Subjects:

The main characteristics of the 35 studies included in the systematic review categorized by their study designs. by Hattapark Dejakaisaya (22238613)

Subjects:

DataSheet1_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”

DataSheet3_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”

DataSheet2_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”

DataSheet4_Significant nocturnal wakefulness after sleep onset in metabolic dysfunction–associated steatotic liver disease.PDF by Sofia Schaeffer (20379954)

“…HC 8.5 vs. 5.5, p = 0.0036), longer wakefulness after sleep onset (MASLD vs. HC 45.4 min vs. 21.3 min, p = 0.0004), and decreased sleep efficiency (MASLD vs. …”

(a) Histogram of relative phase at all steps for all participants. by Shinnosuke Hase (20917896)

Data. by Aroon La-up (14095691)

“…This study found a statistically significant decrease in BMD in the group with the lowest U-Cd levels (<2.0 μg/g creatinine, p = 0.001) and in the overall sample (from 0.392 ± 0.079 μg/g creatinine in 2019 to 0.384 ± 0.094 μg/g creatinine in 2022, p = 0.004). …”

Overall analysis of randomized controlled trials. by Solima Sabeel (9545738)

Subjects:

Newcastle-Ottawa scale. by Solima Sabeel (9545738)

Subjects: